1. Search Result
Search Result
Results for "

PARylation

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16106
    Talazoparib
    95+ Cited Publications

    BMN-673; LT-673

    PARP Cancer
    Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .
    Talazoparib
  • HY-128760
    COH34
    1 Publications Verification

    Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    COH34 is a potent and specific poly(ADP-ribose) glycohydrolase (PARG) inhibitor with an IC50 of 0.37 nM. COH34 binds to the catalytic domain of PARG (Kd=0.547 μM), thereby prolonging PARylation at DNA lesions and trapping DNA repair factors .
    COH34
  • HY-16106A

    (8R,9S)-BMN-673; (8R,9S)-LT-673

    PARP Cancer
    (8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an PARP1 inhibitor, with an IC50 of 144 nM .
    (8R,9S)-Talazoparib
  • HY-E70238

    Nicotinamide 2-azidoadenine dinucleotide

    Glutamate Dehydrogenase (GLDH) Others
    2-Azido-NAD is a NAD + analog that can be used for visualization of intracellular Poly(ADP ribos)ylation (PARylation) processes .
    2-Azido-NAD
  • HY-178032

    PARP Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis STING Cancer
    PARP1-IN-44, an Olaparib (HY-10162) derivative, is an orally active PARP1 inhibitor (IC50 = 0.6 nM), and also inhibits PARP2 (IC50 = 1.0 nM) and PARP7 (IC50 = 7.5 nM). PARP1-IN-44 has selective antiproliferative activity against BRCA-deficient cancer cells with minimal toxicity to normal cells. PARP1-IN-44 induces G2/M phase arrest, promotes apoptosis, elevates ROS levels, disrupts mitochondrial membrane potential. PARP1-IN-44 suppresses PARylation while increasing γH2AX accumulation. PARP1-IN-44 activates the cGAS-STING pathway, upregulating IFN-β and CXCL10 expression. PARP1-IN-44 enhancing CD8+ T cell infiltration in a CT26 tumor mouse model, demonstrating robust in vivo antitumor efficacy .
    PARP1-IN-44
  • HY-14687

    (rac)-BMN-673; (rac)-LT-673

    PARP Cancer
    (rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for PARP1/2 with Ki of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC50 of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC50 of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models .
    (rac)-Talazoparib
  • HY-136263

    PARP Cancer
    Biotin-NAD + is a PARylation donor and also a substrate of poly (ADP-ribose) polymerase-1 (PARP1). Under the mediation of PARP1, Biotin-NAD + undergoes poly (ADP-ribosyl) ation to generate biotinylated poly (ADP-ribose) polymers. Biotin-NAD + can be used for pull-down assays of PARylated proteins in renal epithelial cells. Biotin-NAD + is applicable to cancer-related research .
    Biotin-NAD+
  • HY-185459

    PARP Epigenetic Reader Domain Cancer
    PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers .
    PCIP-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: